Related Experiment Video
Updated: Apr 22, 2026

High-Content Screening Assay for the Identification of Antibody-Dependent Cellular Cytotoxicity Modifying Compounds
Published on: August 18, 2023
[Alemtuzumab, a monoclonal antibody against CD52: hopes and fears]
1Department of Neurology, Chiba University Graduate School of Medicine.
CD52, an antigen expressed on immune cells including mature T lymphocytes, is thought to be involved in immunomodulatory mechanisms. Alemtuzumab is a humanized monoclonal antibody against CD52, which causes a marked and long-term decrease in immune cells, especially CD4-positive T lymphocytes. A few randomized clinical trials have revealed the efficacy of alemtuzumab to be much greater than that of interferon-β in patients with relapsing-remitting multiple sclerosis. However, the development of other autoimmune disorders, including autoimmune thyroid disorders and thrombocytic purpura, because of alemtuzumab application has been considered an obstacle in its widespread use.
CD52, an antigen expressed on immune cells including mature T lymphocytes, is thought to be involved in immunomodulatory mechanisms. Alemtuzumab is a humanized monoclonal antibody against CD52, which causes a marked and long-term decrease in immune cells, especially CD4-positive T lymphocytes. A few randomized clinical trials have revealed the efficacy of alemtuzumab to be much greater than that of interferon-β in patients with relapsing-remitting multiple sclerosis. However, the development of other autoimmune disorders, including autoimmune thyroid disorders and thrombocytic purpura, because of alemtuzumab application has been considered an obstacle in its widespread use.
More Related Videos
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Tumor Immunotherapy

